H. Lawrence Remmel bought $7,000 of ATOS
director at ATOSSA THERAPEUTICS, INC.. 10,000 shares at an average of $0.70, traded Mar 26, 2025, filed Mar 28, 2025.
Score components
- +15RoleDirector
- 0Trade size$7k at market
- +10Relative to holdingsHoldings up 3891%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +8.6%, 3m +25.7%, 6m +22.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-046742, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 26, 2025 | POpen-market purchase Common Stock | +10,000 | $0.70 | $7,000 | 10,257 | Mar 28, 2025 |
Related signals
Other insiders at ATOSSA THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | ATOSbuy ATOSSA THERAPEUTICS, INC. | Steven C Quay President & CEO | $9,887 11,239 shares | +423% | |
| 33Weak | ATOSbuy ATOSSA THERAPEUTICS, INC. | Jonathan Finn director | $44k 25,000 shares | - | |
| 48Moderate | ATOSsell ATOSSA THERAPEUTICS, INC. | Gregory L Weaver Former EVP, CFO, & Director | $33k 50,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.